ASO Author Reflections: Clinical Effectiveness and Safety of Transarterial Chemoembolization: Hepatic Artery Infusion Chemotherapy Plus Tyrosine Kinase Inhibitors With or Without Programmed Cell Death Protein-1 Inhibitors for Unresectable Hepatocellular Carcinoma—A Retrospective Study-Reference-Cited by-同舟云学术

ASO Author Reflections: Clinical Effectiveness and Safety of Transarterial Chemoembolization: Hepatic Artery Infusion Chemotherapy Plus Tyrosine Kinase Inhibitors With or Without Programmed Cell Death Protein-1 Inhibitors for Unresectable Hepatocellular Carcinoma—A Retrospective Study

Published:2024-08-13 Issue: Volume: Page:
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Chen Yue,Luo Tao

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1245/s10434-024-16049-3.pdf

Reference6 articles.

1. Zhou J, Sun H, Wang Z, Cong W, et al. Guidelines for the diagnosis and treatment of primary liver cancer (2022 Edition). Liver Cancer. 2023;12(5):405–44. https://doi.org/10.1159/000530495.

2. He MK, Liang RB, Zhao Y, et al. Lenvatinib, toripalimab, plus hepatic architectural infusion chemotherapy versus Lenvatinib alone for advanced hepatocellular carcinoma. Ther Adv Med Oncol. 2021;13(17):588359211002720. https://doi.org/10.1177/17588359211002720.

3. Finn RS, Ikeda M, Zhu AX, et al. Phase Ib study of Lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2020;38(26):2960–70. https://doi.org/10.1200/JCO.20.00808.

4. Kudo M, Ueshima K, Ikeda M, et al. Randomised, multicentre prospective trial of transitional chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut. 2020;69(8):1492–501. https://doi.org/10.1136/gutjnl-2019-318934.

5. He M, Li Q, Zou R, et al. Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial. JAMA Oncol. 2019;5(7):953–60. https://doi.org/10.1001/jamaoncol.2019.0250.